Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00168428 · ClinicalTrials.gov registry record · Phase 3
A Study Using Botulinum Toxin Type A as Headache Prophylaxis for Migraine Patients With Frequent Headaches
A Phase 3 study, sponsored by Allergan.
- Completed
- Registry status
- Phase 3
- Development phase
- 705
- Enrollment target
NCT00168428 is a Phase 3 study that has completed, run by Allergan. The registered enrollment target is 705 participants.
The verdict
NCT00168428, a Phase 3 study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 705 participants
- Enrollment target
Study Summary
This is a 60 week study including a double-blind phase followed by an open-label phase.
Interventions
- BIOLOGICAL Botulinum Toxin Type A
- OTHER placebo (saline)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 705 participants |
| Start Date | 2006-03 |
| Est. Completion | 2008-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00168428
The ClinicalTrials.gov registry entry for NCT00168428 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 705 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Botulinum Toxin Type A is the first listed.
NCT00168428 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00168428 about?
NCT00168428 is a clinical study titled "A Study Using Botulinum Toxin Type A as Headache Prophylaxis for Migraine Patients With Frequent Headaches". This is a 60 week study including a double-blind phase followed by an open-label phase.
What is the current status of trial NCT00168428?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 705 participants. The study started on 2006-03. Estimated completion is 2008-08.
What interventions are being tested in trial NCT00168428?
The interventions under investigation include: Botulinum Toxin Type A (BIOLOGICAL), placebo (saline) (OTHER).
Who is sponsoring clinical trial NCT00168428?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.